A prominent example of the use of this concept is hyperglycosylated erythropoietin (EPO), marketed as Aranesp® (darbepoetin-α) and used for the treatment of anaemia associated with myelosuppressive chemotherapy and chronic renal insufficiency [64]. Here, EPO is linked to chronic kidney disease.